Prostate-Specific Membrane Antigen-Targeted NIR Phototheranostics for Prostate Cancer

Area of Science:

• Oncology
• Nanotechnology
• Radiochemistry

Background:

• Targeted cancer theranostics integrate diagnostic and therapeutic capabilities for personalized medicine.
• Prostate-specific membrane antigen (PSMA) is a key target for prostate cancer theranostics, with several drugs approved.
• Off-target toxicity remains a significant challenge in conventional and advanced cancer treatments, including chemotherapy and radiotherapy.

Purpose of the Study:

• To review recent advances in phototherapy techniques for prostate cancer treatment.
• To explore near-infrared (NIR)-based phototheranostic strategies targeting PSMA.
• To address the potential of phototherapies to overcome off-target toxicity issues.

Main Methods:

• Review of current literature on phototherapies for prostate cancer.
• Focus on strategies utilizing PSMA as a theranostic target.
• Analysis of near-infrared (NIR) based phototheranostic approaches.

Main Results:

• Phototherapies present a viable alternative to mitigate off-target toxicity in prostate cancer.
• PSMA-targeted NIR phototheranostics show significant potential for improved treatment efficacy.
• Recent developments offer new avenues for personalized prostate cancer management.

Conclusions:

• Phototherapies, particularly NIR-based strategies targeting PSMA, hold promise for reducing off-target toxicity in prostate cancer.
• Further research is needed to enhance the translational potential of these phototheranostic techniques.
• These advancements represent a significant step towards safer and more effective personalized cancer therapies.